A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels

Human Genetics

Volumn 124, Issue 1, 2008, Pages 81-88

  Sabater Lleal, Maria ^a   Buil, Alfonso ^a   Souto, Juan Carlos ^a   Alamsy, Laura ^b   Borrell, Montserrat ^a   Lathrop, Mark ^c   Blangero, John ^b   Fontcuberta, Jordi ^a   Soria, José Manuel ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c CENTRE NATIONAL DE GÉNOTYPAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA MARKER; PROTEIN CPB2; STRUCTURAL PROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHROMOSOME 13; CHROMOSOME 19; CHROMOSOME 5P; CHROMOSOME 7Q; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC MODEL; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INFANT; INHERITANCE; LINKAGE ANALYSIS; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; QUANTITATIVE TRAIT LOCUS MAPPING; RISK FACTOR; SPAIN; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; CARBOXYPEPTIDASE U; CHILD; CHILD, PRESCHOOL; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFANT, NEWBORN; INHERITANCE PATTERNS; LINKAGE (GENETICS); LOD SCORE; MALE; MIDDLE AGED; MODELS, GENETIC; THROMBOSIS;

EID: 46949083746     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-008-0527-3     Document Type: Article

References (41)

1. Almasy L, Blangero J (1998) Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62:1198-1211
2. Almasy L, Blangero J (2004) Exploring positional candidate genes: linkage conditional on measured genotype. Behav Genet 34:173-177
3. Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ (2002) Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359:667-671
4. Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270:14477-14484
5. Bladbjerg EM, de Maat MP, Christensen K, Bathum L, Jespersen J, Hjelmborg J (2006) Genetic influence on thrombotic risk markers in the elderly - a Danish twin study. J Thromb Haemost 4:599-607
6. Blangero J, Williams JT, Almasy L (2000) Robust LOD scores for variance component-based linkage analysis. Genet Epidemiol 19(Suppl 1):S8-S14
7. Boehnke M, Lange K (1984) Ascertainment and goodness of fit of variance component models for pedigree data. Prog Clin Biol Res 147:173-192
8. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML (1999) Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 38:6547-6558
9. Boffa MB, Maret D, Hamill JD, Bastajian N, Crainich P, Jenny NS, Tang Z, Macy EM, Tracy RP, Franco RF, Nesheim ME, Koschinsky ML (2008) Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: A functional analysis. Blood 111:183-189
10. Bouma BN, Marx PF, Mosnier LO, Meijers JC (2001) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101:329-354
11. Brouwers GJ, Vos HL, Leebeek FW, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB (2001) A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98:1992-1993
12. de Bruijne EL, Murad SD, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW (2007) Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 97:181-185
13. Dyke B (1995) PEDSYS: A pedigree data management system. User's manual. Southwest Foundation for Biomedical Research, San Antonio
14. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA (2004) Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103:3773-3776
15. Falconer M (1996) Introduction to quantitative genetics. Longman Group Ltd, Essex
16. Feingold E, Brown PO, Siegmund D (1993) Gaussian models for genetic linkage analysis using complete high-resolution maps of identity by descent. Am J Hum Genet 53:234-251
17. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA (2001) Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: Relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86:510-517
18. Frere C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC (2005) Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 94:373-379
19. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I (2001) Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97:2053-2058
20. Hopper JL (2002) The Australian twin registry. Twin Res 5:329-336
21. Hopper JL, Mathews JD (1982) Extensions to multivariate normal models for pedigree analysis. Ann Hum Genet 46:373-383
22. Juhan-Vague I, Morange PE (2003) Very high TAFI antigen levels are associated with a lower risk of hard coronary events: The PRIME Study. J Thromb Haemost 1:2243-2244
23. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22:867-873
24. Knoefler R, Ludwig K, Kostka H, Kuhlisch E, Siegert G, Suttorp M (2003) The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients. Semin Thromb Hemost 29:575-583
25. Kostka H, Kuhlisch E, Schellong S, Siegert G (2003) Polymorphisms in the TAFI gene and the risk of venous thrombosis. Clin Lab 49:645-647
26. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 27:955-962
27. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
28. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34:1038-1040
29. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I (2005) TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: The PRIME study. J Thromb Haemost 3:1503-1510
30. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN (1998) Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80:829-835
31. Peetz D, Victor A, Adams P, Erbes H, Hafner G, Lackner KJ, Hoehler T (2004) Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost 92:344-351
32. Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J (2003) Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34:2387-2391
33. Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J (2004) Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89:880-881
34. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP (2002) Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88:1020-1025
35. Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, Coll I, Felices R, Stone W, Fontcuberta J, Blangero J (2000a) Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Hum Genet 67:1452-1459
36. Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J (2000b) Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 101:1546-1551
37. Tregouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L (2001) Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 109:191-197
38. Tsai SP, Drayna D (1992) The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13. Genomics 14:549-550
39. van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95:2855-2859
40. Vanhoof G, Wauters J, Schatteman K, Hendriks D, Goossens F, Bossuyt P, Scharpe S (1996) The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics 38:454-455
41. Warren DM, Cole SA, Dyer TD, Soria JM, Souto JC, Fontcuberta J, Blangero J, Maccluer JW, Almasy L (2006) A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans. Hum Biol 78:329-339